Catalyst Wire Dossier Catalyst Wire Dossier

Tacrolimus ophthalmic suspension 0.1%

tacrolimus · Astellas Pharma Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tacrolimus ophthalmic suspension 0.1%, covering 2008-04-04 to 2008-04-04. Get the full timeline:

Most recent: Clinical Trial Update: Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis [Phase 3]

See pricing